R&D Systems Inc. Tocris Bioscience Boston Biochem

TAK 165

Cat. No. 3599

TAK 165 C25H23F3N4O2 [366017-09-6]

Price and Availability

For TAK 165 pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: Mubritinib

Chemical Name: 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-1,2,3-triazole

Biological Activity

Potent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.

Technical Data

M.Wt:
468.47
Formula:
C25H23F3N4O2
Solubility:
Soluble to 75 mM in DMSO and to 5 mM in ethanol
Purity:
>99 %
Storage:
Store at +4°C
CAS No:
366017-09-6

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet

References

Sridhar et al (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 4 397. PMID: 12850190.

Nagasawa et al (2006) Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int.J.Urol. 13 585.

Spector et al (2007) Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res. 9 205.

If you know of a relevant citation for this product please let us know.

Keywords: TAK 165, supplier, Potent, selective, ErbB2, inhibitors, Epidermal, Growth, Factor, Receptors, Her, EGFR, Receptor, Tyrosine, Kinases, RTKs, TAK165

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Guide

Highlights over 350 products for cancer research. Request a copy or view PDF today.

divider line

Kinases Product Listing

Kinases Product Listing

Highlights over 350 products for kinase research. Request a copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Some of the most potent
kinase inhibitors all on one plate

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

divider line

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

Schizophrenia Poster

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.

divider line

New Product Guide

NPG

Highlights 140 new products added in the first half of 2014. Request a copy or view PDF today.

divider line

New Products in this Area

Toceranib

Potent PDGFR and VEGFR inhibitor

NVP ADW 742

ATP-competitive inhibitor of IGF1R

KRCA 0008

Potent Ack1 and ALK dual inhibitor; orally bioavailable

DDR1-IN-1 dihydrochloride

Selective DDR1 inhibitor

HNGF6A

Humanin analog; increases insulin sensitivity

HNGF6A

Humanin analog; increases insulin sensitivity

GSK 1838705

Potent and selective IR and IGF1R inhibitor; antitumor

GSK 1838705

Potent and selective IR and IGF1R inhibitor; antitumor

SUN 11602

Basic fibroblast growth factor (bFGF) mimetic; neuroprotective

SUN 11602

Basic fibroblast growth factor (bFGF) mimetic; neuroprotective

Sign-up for new product e-alerts
divider line

Bio-Techne Events

Neuroscience 2014

Neuroscience 2014

November 15 - 19, 2014

Washington D.C., USA